Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

Kambiz N Alavian,Steven I Dworetzky,Laura Bonanni,Ping Zhang,Silvio Sacchetti,Maria A Mariggio,Marco Onofrj,Astrid Thomas,Hongmei Li,Jamie E Mangold,Armando P Signore,Ulrike Demarco,Damon R Demady,Panah Nabili,Emma Lazrove,Peter J S Smith,Valentin K Gribkoff,Elizabeth A Jonas
DOI: https://doi.org/10.1016/j.brainres.2012.01.046
2012-03-29
Abstract:Cellular stress or injury can result in mitochondrial dysfunction, which has been linked to many chronic neurological disorders including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Stressed and dysfunctional mitochondria exhibit an increase in large conductance mitochondrial membrane currents and a decrease in bioenergetic efficiency. Inefficient energy production puts cells, and particularly neurons, at risk of death when energy demands exceed cellular energy production. Here we show that the candidate ALS drug dexpramipexole (DEX; KNS-760704; ((6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) and cyclosporine A (CSA) inhibited increases in ion conductance in whole rat brain-derived mitochondria induced by calcium or treatment with a proteasome inhibitor, although only CSA inhibited calcium-induced permeability transition in liver-derived mitochondria. In several cell lines, including cortical neurons in culture, DEX significantly decreased oxygen consumption while maintaining or increasing production of adenosine triphosphate (ATP). DEX also normalized the metabolic profile of injured cells and was protective against the cytotoxic effects of proteasome inhibition. These data indicate that DEX increases the efficiency of oxidative phosphorylation, possibly by inhibition of a CSA-sensitive mitochondrial conductance.
What problem does this paper attempt to address?